3. Oligomeric Proanthocyanidins Extend Lifespan of SAMP8
Increased longevity is one of the most common desires of human beings. Therefore, anti-aging research is ultimately focused on lifespan extension. However, no convincing strategy based on scientific evidence has been suggested, except for dietary restriction [
8]. Lifespan extension by dietary restriction has been observed over the years in many species, including rats, mice, hamsters, dogs, fish, invertebrates, and yeast. Despite these very encouraging results, clinical application is complex and limited. Regarding this point, although various dietary restriction mimetics, such as glycolytic inhibitors and antioxidants, have been suggested, scientific evidence must be accumulated to support their application [
8]. For this reason, the search for novel anti-aging agents to elicit the same beneficial effects as caloric restriction without side effects and toxicity has attracted much attention.
The lifespan of SAMP8 mice were significantly decreased compared to control strain SAM-resistance/1 (SAMR1, as controls), whereas, the administration of oligomers extended the lifespan, as shown in
Figure 2. However, the lifespan does not extend in response to an increase in the oral dose of oligomers. The bioactivity of catechin derivatives is related to their structural phenolic groups. The increase in the level of polymerization means a rise in phenolic group contents. Previously, we demonstrated that proanthocyanidins showed strong antioxidative activities accompanying with monomeric catechin derivatives
in vitro [
9]. Many researchers have suggested that antioxidative activities are associated with a delay in the aging process and extension of the lifespan in various organisms [
10]. Actually, we demonstrated that oligomers increased Sirt1 expression, a related protein of longevity extension, in a cellular senescence model [
5]. Therefore, we expected oligomeric proanthocyanidins to exert a powerful activity to extend the lifespan due in part to antioxidative effects.
Figure 2.
Effects of oligomers on lifespan of SAM. Forty-five or forty-six-week-old SAMP8 mice were administered vehicle (Veh, water p.o., n = 10), while another two groups were administered oligomers orally at doses of 1 or 10 mg/kg body weight/day (n = 10) using a stomach tube until death. For the remaining group of mice, the mean food intake was restricted to 60% until death (n = 10). SAMR1 mice (45–46 weeks old, n = 10) were used as a control group. (A) Effects of oligomers on survival of SAMP8. (B) Lifespan index based on survival data. Open circle: SAMR1; closed circle: SAMP8 (Veh); open triangle: SAMP8 (oligomers at 1 mg/kg B.W./day); closed triangle: SAMP8 (oligomers at 10 mg/kg B.W./day); gray square: SAMP8 (60% food restriction).
Figure 2.
Effects of oligomers on lifespan of SAM. Forty-five or forty-six-week-old SAMP8 mice were administered vehicle (Veh, water p.o., n = 10), while another two groups were administered oligomers orally at doses of 1 or 10 mg/kg body weight/day (n = 10) using a stomach tube until death. For the remaining group of mice, the mean food intake was restricted to 60% until death (n = 10). SAMR1 mice (45–46 weeks old, n = 10) were used as a control group. (A) Effects of oligomers on survival of SAMP8. (B) Lifespan index based on survival data. Open circle: SAMR1; closed circle: SAMP8 (Veh); open triangle: SAMP8 (oligomers at 1 mg/kg B.W./day); closed triangle: SAMP8 (oligomers at 10 mg/kg B.W./day); gray square: SAMP8 (60% food restriction).
To elucidate the related mechanisms, the expression of Sirt1 was observed. Sir2 is an NAD
+-dependent deacetylase implicated in the regulation of lifespan in species as diverse as yeast, worms, and flies [
11]. Yeast Sir2 is a heterochromatin component that silences transcription at the silent mating loci, telomeres, and ribosomal DNA [
12]. In addition, it suppresses recombination in ribosomal DNA and modulates the longevity of most organisms, including mammals [
13,
14]. Therefore, the enzymatic activity of Sir2 may indicate its usefulness as an effective caloric restriction mimetic [
15]. Among the seven mammalian homologs of Sir2, Sirt1 is the human ortholog of yeast Sir2 and the best-characterized member of mammalian sirtuins. Recently, we showed that pretreatment with oligomers significantly increased Sirt1 expression in a cellular senescence model [
5]. Therefore, in the present study, we investigated the effect of oligomers on the expression of Sirt1 in the SAM model.
Resveratrol has been reported to promote the fitness and survival of simple organisms such as
Saccharomyces cerevisiae [
16,
17] as well as mice fed high-calorie diets [
18,
19] by activation of Sirt1. Moreover, we previously clarified that oligomers increased Sirt1 expression in a cellular senescence model [
5]. Therefore, the effect of oligomers on Sirt1 was compared with resveratrol
in vivo. We expected the administration of oligomers to increase the expression and activation of Sirt1 in the brain and to slow aging-related deteriorations of SAMP8. In this study, the administration of oligomers slightly elevated Sirt1 expression in the brain of SAMP8, but not significant (
Figure 3). The treatment of resveratrol did not have any effect on Sirt1.
Figure 3.
Effects of oligomers on Sirt1 expression in the brain of SAM. Forty-five-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 5), oligomers (O (50), 50 mg/kg B.W./day, p.o., n = 5), or resveratrol (Res (90), 90 mmol/kg B.W./ day, p.o., n = 5). After 5 weeks of administration, brain lysates were immunoblotted with antibodies for Sirt1. Sirt 1 expression intensities were divided by β-actin expression. SAMR1 mice were used as a control (Cont, n = 4).
Figure 3.
Effects of oligomers on Sirt1 expression in the brain of SAM. Forty-five-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 5), oligomers (O (50), 50 mg/kg B.W./day, p.o., n = 5), or resveratrol (Res (90), 90 mmol/kg B.W./ day, p.o., n = 5). After 5 weeks of administration, brain lysates were immunoblotted with antibodies for Sirt1. Sirt 1 expression intensities were divided by β-actin expression. SAMR1 mice were used as a control (Cont, n = 4).
Dietary restriction as an effective method for the extension of longevity has also been reported to induce stereotypical behaviors such as rearing and jumping independent of the lifespan [
20]. In behavioral analyses, we showed that rearing, jumping, and hanging from the lid of the cage in 60% food-restricted SAMP8 markedly increased compared with vehicle-treated SAMP8. Surprisingly, oligomer-treated SAMP8 did not show an increase in these stereotypical behaviors (
Figure 4). Moreover, in inclined plane and voluntary running tests performed to observe differences in motor function, we found no significant difference in the motor function among all SAMP8 groups (
Figure 5). These results indicate that stereotypical behaviors shown in the 60% food-restricted group have no relationship with motor function. It has been reported that dietary restriction may induce anxiety-like behavior by the down-regulation of corticotrophin-releasing factor [
21]. Diet-restricted rats showed stereotypy by an increase of dopamine receptor signaling. Chen
et al. [
20] demonstrated that stereotypical behaviors brought about by caloric restriction were eliminated in Sirt1-knockout mice, indicating that Sirt1 activation may cause stereotypical behaviors on dietary restriction. In our study, although the lifespan was extended by oligomers as well as 60% food restriction, mice administered oligomers did not show stereotypical behaviors, like Sirt1-knockout mice undergoing food restriction.
Figure 4.
Effects of oligomers on stereotypical behaviors. Forty-five or forty-six-week-old SAMP8 mice were administered vehicle (Veh, water p.o., n = 4), while another two groups were administered oligomers orally at doses of 10 mg/kg body weight/day (O (10), n = 4) using a stomach tube until death. For the remaining group of mice, the mean food intake was restricted to 60% until death (FR, n = 4). SAMR1 mice (Cont, 45–46 weeks old, n = 4) were used as a control group. One hundred and thirty-nine days after the start of administration, actions of rearing up on the hindlimbs and jumping from the bottom of the cage were counted for 15 min (A, B). The time spent hanging from the lid was measured for 10 min (C). Administration was continued during the tests. a p = 0.0034 (Student’s t-test); * p < 0.05 (One-way ANOVA, post-hoc Bonferroni’s test).
Figure 4.
Effects of oligomers on stereotypical behaviors. Forty-five or forty-six-week-old SAMP8 mice were administered vehicle (Veh, water p.o., n = 4), while another two groups were administered oligomers orally at doses of 10 mg/kg body weight/day (O (10), n = 4) using a stomach tube until death. For the remaining group of mice, the mean food intake was restricted to 60% until death (FR, n = 4). SAMR1 mice (Cont, 45–46 weeks old, n = 4) were used as a control group. One hundred and thirty-nine days after the start of administration, actions of rearing up on the hindlimbs and jumping from the bottom of the cage were counted for 15 min (A, B). The time spent hanging from the lid was measured for 10 min (C). Administration was continued during the tests. a p = 0.0034 (Student’s t-test); * p < 0.05 (One-way ANOVA, post-hoc Bonferroni’s test).
Figure 5.
Effects of oligomers on motor function. Forty-five or six-week-old SAMP8 mice were administered vehicle (Veh, water p.o., n = 4), while another two groups were administered oligomers orally at doses of 10 mg/kg body weight/day (O (10), n = 4) using a stomach tube until death. For the remaining group of mice, the mean food intake was restricted to 60% until death (FR, n = 4). SAMR1 mice (Cont, 45-46 weeks old, n = 4) were used as a control group. One hundred and thirty-nine days after the start of administration, the time spent on the inclined surface without dropping was measured (A). The number of rotations measured for 30 min (B). Administration was continued during the tests. a p = 0.0159 (A: Student’s t-test).
Figure 5.
Effects of oligomers on motor function. Forty-five or six-week-old SAMP8 mice were administered vehicle (Veh, water p.o., n = 4), while another two groups were administered oligomers orally at doses of 10 mg/kg body weight/day (O (10), n = 4) using a stomach tube until death. For the remaining group of mice, the mean food intake was restricted to 60% until death (FR, n = 4). SAMR1 mice (Cont, 45-46 weeks old, n = 4) were used as a control group. One hundred and thirty-nine days after the start of administration, the time spent on the inclined surface without dropping was measured (A). The number of rotations measured for 30 min (B). Administration was continued during the tests. a p = 0.0159 (A: Student’s t-test).
4. Oligomeric Proanthocyanidins Improve Memory and Enhance Phosphorylation of VEGFR-2 in SAMP8
SAMP8 developed age-related cognitive deficit at as early as 4 months and had a short lifespan relative to SAM-resistance/1 (SAMR1). SAMP8 show a decrease in the release of acetylcholine and noradrenaline in comparison with age-matched SAMR1 [
22,
23]. Many age-dependent alterations in various brain regions such as the cerebral cortex and hippocampus at an early stage in SAMP8 have been suggested as causes of memory deficit [
24,
25]. In the hippocampus, there was a greater increase of glial fibrillary acidic protein as an astrocyte marker in CA1-3 regions of SAMP8 compared with age-matched SAMR1, indicating enhanced reactive gliosis in aged SAMP8 [
26]. Tanaka
et al. [
27] reported the severe loss of oligodendrocytes in the hippocampal CA1 of SAMP8. Moreover, neuronal loss and lower-level expressions of glial cell line-derived neurotrophic factor in the hippocampal CA1 associated with memory impairment of SAMP8 were reported [
28]. Therefore, hippocampal dysfunctions of SAMP8 have been considered to be a major cause of age-dependent memory impairment. Various candidate therapeutic agents for memory dysfunction in SAMP8 have been reported, such as acetyl-L-carnitine, α-lipoic acid, and Choto-san (a herbal formula medicine), as well as caloric restriction [
29,
30,
31,
32]. In those studies, oxidative stress was focused on as a cause of memory impairment in SAMP8, although the change of oxidative stress was limited in the cerebral cortex. Additionally, neuronal morphological evaluations were insufficient in those studies.
In our study, oligomers improved spatial memory and object recognition memory in SAMP8. The memory improvements seen in 18- and 38-week-old SAMP8 led to memory levels almost the same as those of SAMR1 (
Figure 6 and
Figure 7). To investigate the neurological changes brought about by the oral administration of oligomers, we carried out immunohistological analysis of the brain of 59-week-old SAMP8.
Figure 8 shows the effect of oligomers on axons, dendrites, and synapses in the oriens and radiatum of hippocampal CA1; oriens, lucidem and radiatum of hippocampal CA3; and molecular layer and hilus of the dendate gyrus (DG). The expression levels of neurofilament-H (p-NF-H; axon marker) were increased in oligomer-administered compared with vehicle-treated mice. The expression levels of microtubule-associated proteins (MAP) 2a and 2b (MAP2; dendrite marker) and synaptophysin were slightly increased in oligomer-administered mice. In particular, the expression of p-NF-H significantly increased in the hippocampal CA1 by oligomer administration. p-NF-H is used as a marker of axons, since the phosphorylated form of NF-H is translocated into axons [
33]. In the hippocampus of aged mice, fragments of degenerated axons were also increased, although reductions of neuronal numbers are small in this region [
34]. Axonal termination to the spine is a necessary step for synaptogenesis. Considering synaptic losses in the hippocampal CA1 and CA3 and the parietal cortex in SAMP8 [
35], as well as in the hippocampal CA1, CA3, and DG in aged rats [
36], axonal regeneration is important for improving the hippocampal function. Therefore, the increased density of axons in the hippocampal CA1 was suggested to have a protective role against memory loss with aging.
Figure 6.
Effects of oligomers on spatial memory deficit in SAMP8. Eighteen-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 6; closed circles) or oligomers (10 mg/kg body weight/day, p.o., n = 6; open squares or 100 mg/kg body weight/day, p.o., n = 5; closed squares) for 5 weeks. SAMR1 were used as a control (Cont, n = 5; open circles). Fifteen days after the start of administration, memory acquisition tests were continued for 6 days in a Morris water maze. Administration was continued during the tests. Escape latencies to a hidden platform were measured (A). The swimming velocities of mice in the memory acquisition test are shown (B). Thirty-eight-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 7) or oligomers (O (10), 10 mg/kg body weight/day, p.o., n = 7 or O (50), 50 mg/kg body weight/day, p.o., n = 7). Age-matched SAMR1 were used as a control (Cont, n = 7). Twenty-eight days after administration started, an object location test was performed. The preference index was defined as the number of times a mouse made contact with any one of the objects (training session) or the moved object (test session) out of the total number of times the mouse made contact with both objects (%) (C). * p < 0.05 vs. Veh. (A and B: Repeated measures two-way ANOVA followed by Dunnett’s or Bonferroni’s post-hoc test); * p < 0.05 (C: One-way ANOVA followed by Bonferroni’s post-hoc test); a p = 0.0005; b p = 0.0213 (C: paired t-test).
Figure 6.
Effects of oligomers on spatial memory deficit in SAMP8. Eighteen-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 6; closed circles) or oligomers (10 mg/kg body weight/day, p.o., n = 6; open squares or 100 mg/kg body weight/day, p.o., n = 5; closed squares) for 5 weeks. SAMR1 were used as a control (Cont, n = 5; open circles). Fifteen days after the start of administration, memory acquisition tests were continued for 6 days in a Morris water maze. Administration was continued during the tests. Escape latencies to a hidden platform were measured (A). The swimming velocities of mice in the memory acquisition test are shown (B). Thirty-eight-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 7) or oligomers (O (10), 10 mg/kg body weight/day, p.o., n = 7 or O (50), 50 mg/kg body weight/day, p.o., n = 7). Age-matched SAMR1 were used as a control (Cont, n = 7). Twenty-eight days after administration started, an object location test was performed. The preference index was defined as the number of times a mouse made contact with any one of the objects (training session) or the moved object (test session) out of the total number of times the mouse made contact with both objects (%) (C). * p < 0.05 vs. Veh. (A and B: Repeated measures two-way ANOVA followed by Dunnett’s or Bonferroni’s post-hoc test); * p < 0.05 (C: One-way ANOVA followed by Bonferroni’s post-hoc test); a p = 0.0005; b p = 0.0213 (C: paired t-test).
Figure 7.
Effects of oligomers on object recognition memory deficit in SAMP8. Eighteen-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 6) or oligomers (O (10), 10 mg/kg body weight/day, p.o., n = 6 or O (100), 100 mg/kg body weight/day, p.o., n = 5). Age-matched SAMR1 were used as a control (Cont, n = 5). Twenty-four days after the start of administration, a novel object recognition test was performed (A). Thirty-eight-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 7) or oligomers (O (10), 10 mg/kg body weight/day, p.o., n = 7 or O (50), 50 mg/kg body weight/day, p.o., n = 7). Age-matched SAMR1 were used as a control (Cont, n = 7). Twenty-three days after the start of administration, a novel object recognition test was performed (B). The preference index was defined as the number of times a mouse made contact with any one of the objects (training session) or the novel object (test session) out of the total number of times the mouse made contact with both objects (%). * p < 0.05 (One-way ANOVA followed by Bonferroni’s post-hoc test); a p = 0.0174; b p = 0.0014 (paired t-test).
Figure 7.
Effects of oligomers on object recognition memory deficit in SAMP8. Eighteen-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 6) or oligomers (O (10), 10 mg/kg body weight/day, p.o., n = 6 or O (100), 100 mg/kg body weight/day, p.o., n = 5). Age-matched SAMR1 were used as a control (Cont, n = 5). Twenty-four days after the start of administration, a novel object recognition test was performed (A). Thirty-eight-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 7) or oligomers (O (10), 10 mg/kg body weight/day, p.o., n = 7 or O (50), 50 mg/kg body weight/day, p.o., n = 7). Age-matched SAMR1 were used as a control (Cont, n = 7). Twenty-three days after the start of administration, a novel object recognition test was performed (B). The preference index was defined as the number of times a mouse made contact with any one of the objects (training session) or the novel object (test session) out of the total number of times the mouse made contact with both objects (%). * p < 0.05 (One-way ANOVA followed by Bonferroni’s post-hoc test); a p = 0.0174; b p = 0.0014 (paired t-test).
Figure 8.
Effects of oligomers on the decrease of axons, dendrites, and synapses in the hippocampus. Fifty-nine-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 3) or oligomers (O (50), 50 mg/kg body weight/day, p.o., n = 3). After seven days of administration, brain slices were immunostained with p-NF-H (A), MAP2 (B), and synaptophysin antibodies (C). The intensities of immuno-positive areas in the hippocampus were quantified. a p = 0.0243; b p = 0.0344 (Student’s t-test).
Figure 8.
Effects of oligomers on the decrease of axons, dendrites, and synapses in the hippocampus. Fifty-nine-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 3) or oligomers (O (50), 50 mg/kg body weight/day, p.o., n = 3). After seven days of administration, brain slices were immunostained with p-NF-H (A), MAP2 (B), and synaptophysin antibodies (C). The intensities of immuno-positive areas in the hippocampus were quantified. a p = 0.0243; b p = 0.0344 (Student’s t-test).
Previous studies suggested that oxidative stress is a major cause of memory impairment in SAMP8. Hippocampus-specific modulation by oligomers is not explained by an anti-oxidative effect, since only the cerebral cortex is susceptible to oxidative stress in SAMP8 and not the hippocampus [
37]. Therefore, to investigate target molecules by the oral administration of oligomers in the brain of SAMP8, we performed a receptor tyrosine kinase phosphorylation antibody array, and clarified that oligomer treatment increased the phosphorylation of VEGFR-2, as shown in
Figure 9. In addition the effect of oligomers on the expression in various brain regions was also investigated (
Figure 10). Increased expressions of p-VEGFR-2 were observed in the cerebral cortex, hypothalamus, choroid plexus, and hippocampal CA3 layer of SAMP8 (
Figure 11A). In particular, the p-VEGFR-2 level in the hypothalamus of oligomer-treated SAMP8 was significantly increased compared with that in vehicle-treated mice. On the other hand, expression levels of VEGFR-2 in an SAMP8 group administered oligomers did not show significant changes compared with vehicle-administered mice in all brain regions observed (
Figure 11B). In neurons, stimulation by VEGFR-2 among protein tyrosine kinase receptors of VEGF is linked to Akt/PKB activation and neuronal protection in hypoxic preconditioning [
38]. Moreover, VEGFR-2 mediated a protective effect through phosphatidylinositol-3-kinase/Akt- and mitogen-activated protein/extracellular signal-regulated kinase-signaling pathways in glutamate-induced toxicity [
39]. In particular, memory enhancement in recombinant adeno-associated viral vectors expressing human VEGF-injected mice was inhibited by the injection of dominant-negative mutant VEGFR-2 [
40]. This indicates that VEGF/VEGFR-2 is directly associated with neuronal signaling. VEGF also exerts indirect effects on neurons. Moreover, the topical administration of VEGF to the surface of the brain reduces the infarct size, and intraventricular VEGF enhanced the survival of newly generated neurons in the dentate gyrus and subventicular zones after focal cerebral ischemia [
41]. In this study, we firstly showed that memory enhancement through oligomer treatment was eliminated by SU1498, an inhibitor of VEGFR-2 (
Figure 12). Considering that VEGF-E-induced memory was also inhibited by SU1498, oligomers or their metabolites may regulate memory by the activation of VEGFR-2.
We found that the administration of oligomers increased the phosphorylation of VEGFR-2 in the hippocampal CA3 region, suggesting that oligomeric metabolites directly affect the hippocampus, like the VEGFR-2 ligand. It has been reported that Ca
2+ influx and synaptic transmission by VEGF in the hippocampus influences the generation of long-term changes in synaptic efficacy [
42]. VEGF also stimulates neurite outgrowth via Rho/ROK signaling in cerebral cortical neurons [
43]. Interestingly, changes in the synapes and neurites induced by VEGF are caused by the activation of VEGFR-2 rather than VEGFR-1. Therefore, we speculated that the phosphorylation of VEGFR-2 induced by the administration of oligomers within the hippocampus may be related to an increase in the densities on neurites and synapses in the hippocampus.
The administration of oligomers increased the phosphorylation of VEGFR-2 in the hypothalamus and choroid plexus as well as the hippocampus. The hypothalamus is contained in the Papez circuit. The Papez circuit is a sensory circuit involving the thalamus, sensory cortex (especially the cingulate region), hippocampus, and mammillary body of the hypothalamus [
44]. It has been reported that lesions in the Papez circuit are associated with amnesia and the impairment of recognition memory [
45]. Therefore, we speculate that the hypothalamus is activated by the phosphorylation of VEGFR-2, which may affect the hippocampus through the Papez circuit.
The choroid plexus is made up of numerous villi which project into the ventricles of the brain. Each villus is composed of a single layer of epithelial cells overlying a core of connective tissues and blood capillaries [
46]. The choroid plexus is involved in the most basic aspects of neural function, including maintaining the extracellular milieu of the brain by actively modulating chemical exchange between the cerebrospinal fluid and brain parenchyma, surveying the chemical and immunological status of the brain, detoxifying the brain, secreting a nutritive cocktail of polypeptides, and participating in repair processes following trauma. This diversity of functions may mean that even modest changes in the choroid plexus can have far-reaching effects [
47]. Actually, a host of growth factors and other neuroprotective agents given via the cerebrospinal fluid can minimize the adverse effects of stroke on the rat hippocampus. Multiple functional failures including a decrease of cerebrospinal fluid as well as the atrophy of choroidal epithelial cells shown in normal aging as well as advanced Alzheimer’s disease indicate that the maintenance of cerebrospinal fluid through the choroid plexus may have beneficial effects against neurodegenerative diseases [
48]. Moreover, it was reported that the intracerebroventicular injection of nerve growth factor or insulin-like growth factor-1 improved memory deficit and hippocampal deterioration [
49,
50]. Therefore, we speculate that oligomers may induce the secretion of some peptides after the phosphorylation of VEGFR-2 in the choroid plexus, and then this peptide may induce changes in the hipppocampus.
Figure 9.
Effects of oligomers on phosphorylated VEGFR-2 (p-VEGFR-2) and VEGFR-2 expressions. Fifty-nine-week-old SAMP8 were administered vehicle (Veh, water p.o.) or oligomers (O (50), 50 mg/kg body weight/day, p.o.). After seven days of administration, brain lysates were immunoblotted with antibodies for p-VEGFR-2 (A) or VEGFR-2 (B). Expression intensities were divided by β-actin expressions to calculate ratios. a p = 0.0481 vs. O (50) (Student’s t-test).
Figure 9.
Effects of oligomers on phosphorylated VEGFR-2 (p-VEGFR-2) and VEGFR-2 expressions. Fifty-nine-week-old SAMP8 were administered vehicle (Veh, water p.o.) or oligomers (O (50), 50 mg/kg body weight/day, p.o.). After seven days of administration, brain lysates were immunoblotted with antibodies for p-VEGFR-2 (A) or VEGFR-2 (B). Expression intensities were divided by β-actin expressions to calculate ratios. a p = 0.0481 vs. O (50) (Student’s t-test).
Figure 10.
Effects of oligomers on p-VEGFR-2 and VEGFR-2 expression in various brain regions. Fifty-nine-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 3) or oligomers (O (50), 50 mg/kg B.W./day, p.o., n = 3). After seven days of administration, brain slices were immunostained with p-VEGFR-2 (A) and VEGFR-2 (B) antibodies.
Figure 10.
Effects of oligomers on p-VEGFR-2 and VEGFR-2 expression in various brain regions. Fifty-nine-week-old SAMP8 were administered vehicle (Veh, water p.o., n = 3) or oligomers (O (50), 50 mg/kg B.W./day, p.o., n = 3). After seven days of administration, brain slices were immunostained with p-VEGFR-2 (A) and VEGFR-2 (B) antibodies.
Figure 11.
Intensities of p-VEGFR-2- (A) and VEGFR-2 (B)-positive areas were quantified in the cerebral cortex, hypothalamus and choroid plexus, and the CA1, CA3, and DG of the hippocampus. a p = 0.0429 vs. O (50) (Student’s t-test).
Figure 11.
Intensities of p-VEGFR-2- (A) and VEGFR-2 (B)-positive areas were quantified in the cerebral cortex, hypothalamus and choroid plexus, and the CA1, CA3, and DG of the hippocampus. a p = 0.0429 vs. O (50) (Student’s t-test).